Multi-cohort, cross-species urinary proteomics reveals signatures of LRRK2 dysfunction in Parkinson’s disease

Abstract Pathogenic mutations in Leucine-rich repeat kinase 2 (LRRK2) are the predominant genetic cause of Parkinson’s disease (PD) and often increase kinase activity, making LRRK2 inhibitors promising treatment options. Although LRRK2 kinase inhibitors are advancing clinically, non-invasive readout...

Descripció completa

Dades bibliogràfiques

Autors principals:	Duc Tung Vu, William Sibran, Andreas Metousis, Laurine Vandewynckel, Basak Eraslan, Liesel Goveas, Ericka CM Itang, Claire Deldycke, Adriana Figueroa-Garcia, Réginald Lefèbvre, Johannes Bruno Müller-Reif, Sebastian Virreira Winter, Marie-Christine Chartier-Harlin, Jean-Marc Taymans, Matthias Mann, Ozge Karayel
Format:	Artigo
Idioma:	Inglês
Publicat:	Springer Nature 2026-01-01
Col·lecció:	Molecular Systems Biology
Matèries:	LRRK2 Parkinson’s Disease Urine Proteomics Biomarker
Accés en línia:	https://doi.org/10.1038/s44320-026-00190-0
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!